Ligand ID: RXM Drugbank ID: DB01220(Rifaximin) Indication:Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 2ghv | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE E 325PHE E 329VAL E 394PHE E 501VAL E 328 | 1.55A | 16.94 | None | ||
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 5x58 | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 9 | PHE B 700PHE B 888PHE B 909VAL B 897GLN B 895 | 1.50A | 19.93 | None | ||
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE C 700PHE C 888PHE C 909VAL C 897GLN C 895 | 1.44A | 20.05 | PHE C 700 ( 1.3A)PHE C 888 ( 1.3A)PHE C 909 ( 1.3A)VAL C 897 ( 0.6A)GLN C 895 ( 0.6A) | ||
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | GLN B 766GLU B 707PHE B1044VAL B1042GLN B1036 | 1.34A | 20.05 | None | ||
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 9 | PHE C 700PHE C 888PHE C 909VAL C 897GLN C 895 | 1.52A | 19.90 | None | ||
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 6cs0 | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 9 | PHE B 909PHE B1034VAL B 767PHE B 779VAL B1047 | 1.33A | 19.90 | None | ||
![]() | 6BEE_B_RXMB601_0 (SCAFFOLD PROTEIN D13) | 6nb6 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PHE A 700PHE A 888PHE A 909VAL A 897GLN A 895 | 1.48A | 18.90 | None |